Purchase this article with an account.
H. F. Ulltveit-Moe, A. Takserman, P. Bjerga, L. T. Hashemi, S. Raeder, V. A. Forsaa; A Comparison of Treatment With Intravitreal Ranibizumab and Bevacizumab in Patients With Central Retinal Vein Occlusion Using a "Treat and Extend" Dosing Regimen. Invest. Ophthalmol. Vis. Sci. 2010;51(13):4719.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the effect of intravitreal ranibizumab and bevacizumab on visual acuity (VA), letter gain, and central macular thickness (CMT) in patients with central retinal vein occlusion (CRVO).
We performed a retrospective study of 14 eyes of 14 patients with CRVO of three to 12 months duration of symptoms treated either with ranibizumab (ranibizumab group, n=6) or bevacizumab (bevacizumab group, n=8) on "treat and extend" dosing regimen. VA using Early Treatment Diabetic Retinopathy Study (EDTRS) chart and CMT using optical coherence tomography were obtained at baseline and at 6-month follow-up. Non-parametric statistics were used to compare the treatment groups (Mann-Whitney U test) and to compare 6 months with baseline (Wilcoxon signed ranks test).
The mean number of injections at 6-month follow-up was 6.0 in the ranibizumab group and 5.9 in the bevacizumab group. At baseline, mean VA was 0.93 logMar (range, 0.30-2.00 logMar) in the ranibizumab group and 1.08 logMar (range, 0.30-2.00 logMar) in the bevacizumab group (p=0.66). Mean baseline CMT in the ranibizumab group was 594 µm (range, 382 µm-881 µm) and in the bevacizumab group 865 µm (462 µm-1245 µm) (p=0.11). At 6-month follow-up, mean VA was 0.48 logMar (range, 0.10-0.90 logMar) in the ranibizumab group and 0.45 logMar (range, 0.00-1.00 logMar) in the bevacizumab group (p=0.85). Significant improvements in VA in the ranibizumab group (p=0.04) and in the bevacizumab group (p=0.01) were seen. EDTRS letter gain of 22.5 letters (range, 0-55 letters) in the ranibizumab group and 32.1 letters (range, 15-80 letters) in the bevacizumab group was observed, but no significant difference was found between the groups (p=0.35). Mean 6-month follow-up CMT in the ranibizumab group was 229 µm (range, 184 µm-270 µm) and in the bevacizumab group 334 µm (111 µm-753 µm) (p=0.35). Significant reduction in CMT in the ranibizumab group (p=0.03) and in the bevacizumab group (p=0.01) was observed.
The results from our study indicate significant and sustained effect of intravitreal ranibizumab and bevacizumab individually in patients with CRVO, but no significant difference between the treatment groups using "treat and extend" dosing regimen.
This PDF is available to Subscribers Only